Predicting responsiveness to GLP-1 pathway drugs using real-world data

Abstract Background Medications targeting the glucagon-like peptide-1 (GLP-1) pathway are an important therapeutic class currently used for the treatment of Type 2 diabetes (T2D). However, there is not enough known about which subgroups of patients would receive the most benefit from these medicatio...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaodong Zhu, Michael J. Fowler, Quinn S. Wells, John M. Stafford, Maureen Gannon
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Endocrine Disorders
Subjects:
Online Access:https://doi.org/10.1186/s12902-024-01798-9
Tags: Add Tag
No Tags, Be the first to tag this record!